Gradientech Announces Prominent International Scientific Advisory Board

Report this content

Swedish diagnostics firm Gradientech is proud to announce the appointment of three internationally renowned members to the company’s scientific advisory board, SAB. With their expertise in clinical microbiology, the new advisors will provide valuable support in preparing for a successful market launch of Gradientech’s in vitro diagnostic system for ultra-rapid antibiotic susceptibility testing, claimed to be the fastest among new systems in development.

“To significantly shorten the time to an AST result is of tremendous importance to the patient and the clinical colleague in charge! Anything that we can do to help speed up testing without compromising quality and safety is worth our efforts”, says Gunnar Kahlmeter, member of the SAB.

“All members of our new SAB have been in Gradientech’s advisory network for several years, but we are now formalising the collaboration further to intensify the work and gather the collected knowledge in one place. It is a true honour to work with such experienced advisors” says Sara Thorslund, CEO of Gradientech.

For further information, please contact:
Sara Thorslund, PhD, CEO Gradientech
Tel: +46 736 29 35 80
sara.thorslund@gradientech.se

About Gradientech
Gradientech is a diagnostics company developing the in vitro diagnostic QuickMIC® system, a new platform for antibiotic susceptibility testing based on phenotypic bacterial growth analysis. The system is expected to become the most rapid solution for determining appropriate antibiotic treatment of sepsis patients. Rapid antibiotic susceptibility testing is vital for increasing sepsis patient survival, reducing healthcare costs and lowering the spread of antibiotic resistance. www.gradientech.se